Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Consolidated statements of cash flows

v3.25.0.1
Consolidated statements of cash flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:      
Net loss $ (11,457) $ (29,373) $ (83,661)
Adjustments to reconcile net loss to net cash used in (provided by) operating activities:      
Depreciation and amortization 10,528 10,258 10,584
Finance expense 500 1,646 1,112
Unrealized (gain) loss from hedging transactions 103 (52) (20)
Share-based compensation 17,615 18,127 16,987
Gain on sale of equipment (12) 0 (142)
Changes in operating assets and liabilities:      
Change in operating lease right-of-use assets and liabilities, net (1,078) (1,926) 5,744
Increase in accounts receivable, net (2,127) (9,728) (6,882)
Increase in deferred contract costs (258) (2,873) (459)
Decrease in other current assets 612 617 1,342
Decrease (increase) in other non-current assets (6) (53) 372
(Decrease) increase in accounts payable 3,597 1,255 (4,284)
Increase in deferred revenue 6,432 6,677 15,055
(Decrease) increase in other non-current liabilities 528 961 (1,497)
(Decrease) increase in other liabilities and accrued expenses 5,197 1,426 (316)
Net cash (used in) provided by operating activities 30,174 (3,038) (46,065)
Cash flows from investing activities:      
Purchase of property and equipment, net (1,430) (1,559) (28,257)
Capitalized internal-use software costs (1,304) (821) (2,919)
Decrease (increase) in restricted deposits (552) (206) 1,660
Payment for business combinations, net of cash acquired (15,414) 0 (3,787)
Cash received in relation to business combinations 0 0 294
Net cash used in investing activities (18,700) (2,586) (33,009)
Cash flows from financing activities:      
Proceeds from exercise of stock options 4,677 2,296 2,034
Proceeds from employee share purchase plan 1,486 1,259 2,083
Borrowings (repayments) under Credit Facility (25,000) 0 25,000
Payments of contingent consideration, net 0 (2,363) 0
Net cash provided by (used in) financing activities (18,837) 1,192 29,117
Effect of exchange rates on cash and cash equivalents (500) (1,646) (1,112)
Net decrease in cash and cash equivalents (7,863) (6,078) (51,069)
Cash and cash equivalents, beginning of period 63,869 71,732 77,810
Cash and cash equivalents, end of period 71,732 77,810 128,879
Supplemental disclosure of cash flow information:      
Taxes paid 1,168 1,883 485
Supplemental disclosure of non-cash investing and financing activities:      
Initial public offering costs incurred during the period included in accounts payable and accrued expenses 0 0 (121)
Additions to operating lease right-of-use assets and liabilities 6,064 2,597 9,485
Share-based compensation included in capitalized internal-use software 104 37 0
Proceeds from exercise of share options included in other current assets 29 11 0
Deferred costs of property and equipment incurred during the period included in accounts payable 227 139 116
Deferred payments related to business combinations $ 340 $ 1,269 $ 0